Avidity Biosciences: Strong Buy on Promising Trials and Solid Financials

Wells Fargo analyst Yanan Zhu maintained a Buy rating on Avidity Biosciences (RNA – Research Report) yesterday and set a price target of $50.00.

Yanan Zhu has given his Buy rating due to a combination of factors including Avidity Biosciences’ promising clinical trials and a strong financial position. The initiation of the Phase 3 HARBOR study for the treatment of adults with DM1 is a significant milestone, as the company has already secured Breakthrough Therapy Designation from the FDA for del-desiran, which indicates a potential for expedited development and review. Additionally, Avidity’s financial resources, with a cash position of approximately $915 million, are expected to support its operations well into late 2026, providing a stable foundation for ongoing research and development activities.
Furthermore, the anticipated second-quarter readouts for AOC 1020 in FSHD patients could be a substantial value driver, especially if the data on safety, muscle concentration, and DUX4 downstream gene signatures are favorable. The steady progress of AOC 1044 for DMD44, with data expected in the second half of the year, also contributes to the positive outlook. These upcoming catalysts, combined with the company’s ability to fund its strategic initiatives, support Zhu’s Buy recommendation for Avidity Biosciences.

In another report released on May 10, Needham also maintained a Buy rating on the stock with a $35.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Avidity Biosciences (RNA) Company Description:

Avidity Biosciences Inc is a bio-technology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product candidate AOC 1001, is designed to treat a rare monogenic muscle disease.